For instance Sunitinib is approved after Imatinib resistance formation in gastrointestinal stromal tumors (GIST), and Lapatinib after non-responding to antracycline- or taxane-based chemotherapy in combination with Trastuzumab in HER-2 positive breast cancer. Here, ERBB2 is linked to gastrointestinal stromal tumor.